AVITA MEDICAL Aktie

0,16 EUR 6,4935%

Zu Ihrem Onlinebroker

kaufen verkaufen

AVITA MEDICAL Aktienkurs : 24.05. ( 15 Min. verzögert)
0,164 € Letzter Kurs	6,49% Veränderung	0,154 € Vortag	0,164 € Eröffnungskurs

Realtime:

0,16

6,49%

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
0,164 - 0,164 Tag	0,0000000 - 0,0000000 52 Wochen	0 Tag	686 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

AVITA MEDICAL Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

21.05.

Avita Medical initiates US FDA study of ReCell Spray-On-Skin

NORTHRIDGE, England: Avita Medical, the regenerative medicine company, recently announced that it has commenced enrolment in the US FDA-approved feasibility study for the use...
17.05.

Avita Medical Commences FDA Approval of ReCell Product

Avita Medical, a Northridge-based regenerative medicine company, announced it has initiated an FDA study of its ReCell Spray-On-Skin product for the treatment of raised or discolored scars. The proto…

16.05.

Avita Medical Initiates US FDA Study of Its ReCell® Spray-On-Skin™ for ...

CAMBRIDGE, England--(EON: Enhanced Online News)--Avita Medical Ltd. (ASX: AVH), (OTC: AVMXF), (OTCQX: AVMXY),the regenerative medicine company, today announced that it has commenced enrolment in the US...
14.05.

B. Riley 13th Annual Investor Conference to Feature Expert-Led Information ...

(ATNY) Arabian American Development Company (ARSD) Attunity Inc. (ATTUF) Autobytel Inc. (ABTL) Avita Medical Ltd. (AVMXY) Axesstel Inc. (AXST) AXT Inc. (AXTI) Ballantyne Strong Inc. (BTN) BBCN Bancorp, Inc. (BBCN) Biolase Technology, Inc. (BLTI)...
10.05.

Avita Medical: ReCell® Spray‐On‐Skin™ expanded to include cosmetic treatments

Avita Medical (ASX: AVH, OTCQX: AVMXY) has begun patient enrolment in a feasibility study for the use of ReCell® Spray‐On‐Skin™ in the treatment of hypertrophic dyspigmented scars. The US Food and Dr…